A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy wanes ...

By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

Pfizer Inc. has announced the company has discontinued the development of danuglipron (PF-06882961), an oral glucagon-like ...

Just hours after thousands of U.S. Food and Drug Administration employees were shown the door, Barclay Butler, the agency’s ...

The European Commission (EC) has expanded the approval of Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, to include adults aged 18 to 59 years at increased risk of lower ...